Scisparc Ltd (SPRC)

$1.23 -0.22 (-15.17%)
Market Cap 775,000.00
Revenue (ttm) 1.31M
Net Income (ttm) -6.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -479.39%
Debt to Equity Ratio -30.38
Volume 40,437,801
Avg Vol 2,402,228
Day's Range N/A - N/A
Shares Out 535,000.00
Stochastic %K 39%
Beta 1.66
Analysts Strong Buy
Price Target $20.00

Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. It also sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufac...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 334 47180
Address:
Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv, Israel
roaringcharts
roaringcharts Jan. 14 at 11:23 AM
$BCTX and $SPRC WHENEVER THERE'S GREAT NEWS WATCH FOR THE RUG. BIO TECH RUGS
0 · Reply
roaringcharts
roaringcharts Jan. 14 at 10:48 AM
$SPRC Just look at the charts after a RS.
0 · Reply
69z28
69z28 Jan. 14 at 9:57 AM
$SPRC Ready for this to dip & buy it up!
0 · Reply
MovingFast77
MovingFast77 Jan. 14 at 2:52 AM
$SPRC
0 · Reply
Enzo4u
Enzo4u Jan. 14 at 12:36 AM
$SPRC Will we see another pump?
0 · Reply
roaringcharts
roaringcharts Jan. 13 at 11:00 PM
$SPRC so the ceo here is oz adler is a director at$PLRZ $CMND and they destroyed plrz reverse split after reverse split before it ran so don't be surprised if he hits another offering asap. Offering closes tomorrow so let's see
1 · Reply
Malandro2410
Malandro2410 Jan. 13 at 10:53 PM
$SPRC I hope everyone sells there shares on these bums! You put news out on the day of an offering to destroy the people holdings pockets. Im glad i seen this today and if I were you I would sell on them and drive the price to nothing with there ti y marketcap. That was cringe and disgusting wbt they did to yall. I hope you guys make your money back!
0 · Reply
BreakoutBullz
BreakoutBullz Jan. 13 at 10:23 PM
🛎️ Trade Recap 🛎️ $EVTV ran 🔥💰🎯 +633% from initial .67 call! $AHMA ran 🔥💰🎯 +146% from 6.60 call! $XAIR ran 🔥💰🎯 +105% from 1.30 call! $GELS ran 🔥💰🎯 +53% from 1.10 call! $SPRC ran 🔥💰🎯 +32% from 1.80 call!
0 · Reply
Enzo4u
Enzo4u Jan. 13 at 9:50 PM
$SPRC still a low float even after the offering, but def a turd
0 · Reply
Zackpedia
Zackpedia Jan. 13 at 9:39 PM
$SPRC Told you!
0 · Reply
Latest News on SPRC
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

Jan 13, 2026, 6:55 AM EST - 23 hours ago

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Jan 12, 2026, 4:02 PM EST - 1 day ago

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Neurothera Labs Announces Results of AGM

Jan 8, 2026, 6:00 PM EST - 5 days ago

Neurothera Labs Announces Results of AGM

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:17 AM EST - 14 days ago

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:00 AM EST - 14 days ago

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 9:29 AM EST - 6 weeks ago

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 8:05 AM EST - 6 weeks ago

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

Dec 1, 2025, 8:32 AM EST - 6 weeks ago

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

Nov 26, 2025, 7:38 AM EST - 6 weeks ago

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 20, 2025, 6:42 AM EST - 7 weeks ago

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 7 weeks ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

CMND

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 24, 2025, 7:55 AM EDT - 2 months ago

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Oct 23, 2025, 4:03 PM EDT - 2 months ago

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Oct 23, 2025, 8:55 AM EDT - 2 months ago

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

Oct 22, 2025, 3:30 PM EDT - 2 months ago

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Oct 20, 2025, 7:41 AM EDT - 3 months ago

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 15, 2025, 7:05 AM EDT - 3 months ago

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

Oct 6, 2025, 6:40 AM EDT - 3 months ago

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Sep 29, 2025, 4:03 PM EDT - 3 months ago

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

Sep 25, 2025, 1:06 PM EDT - 3 months ago

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

Sep 25, 2025, 7:05 AM EDT - 3 months ago

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

Aug 28, 2025, 9:24 AM EDT - 4 months ago

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

Aug 28, 2025, 6:45 AM EDT - 4 months ago

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Aug 7, 2025, 7:32 AM EDT - 5 months ago

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

Jul 30, 2025, 4:34 PM EDT - 5 months ago

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Jul 30, 2025, 8:12 AM EDT - 5 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

Jul 22, 2025, 7:32 AM EDT - 6 months ago

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Announces 1-for-21 Reverse Share Split

Jun 24, 2025, 5:03 PM EDT - 7 months ago

SciSparc Announces 1-for-21 Reverse Share Split

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025, 7:32 AM EDT - 8 months ago

SciSparc Announces Publication of Japanese Patent Application

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 25, 2025, 7:59 AM EDT - 9 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

CMND

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Mar 3, 2025, 8:25 AM EST - 11 months ago

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Feb 27, 2025, 8:45 AM EST - 11 months ago

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

Feb 18, 2025, 7:17 AM EST - 11 months ago

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Feb 4, 2025, 9:00 AM EST - 1 year ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 15, 2025, 7:34 AM EST - 1 year ago

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

Jan 13, 2025, 8:41 AM EST - 1 year ago

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Jan 7, 2025, 7:25 AM EST - 1 year ago

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

Jan 6, 2025, 11:04 AM EST - 1 year ago

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 6, 2025, 7:50 AM EST - 1 year ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Dec 31, 2024, 9:24 AM EST - 1 year ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

S&P 500 Edges Lower, SciSparc Shares Surge

Dec 26, 2024, 2:36 PM EST - 1 year ago

S&P 500 Edges Lower, SciSparc Shares Surge

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Dec 26, 2024, 6:46 AM EST - 1 year ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

Dec 16, 2024, 7:40 AM EST - 1 year ago

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

Sep 30, 2024, 9:25 AM EDT - 1 year ago

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

Sep 26, 2024, 9:05 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 23, 2024, 8:17 AM EDT - 1 year ago

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 18, 2024, 4:09 PM EDT - 1 year ago

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

Sep 16, 2024, 4:06 PM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

Sep 11, 2024, 7:40 AM EDT - 1 year ago

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Sep 6, 2024, 7:55 AM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

roaringcharts
roaringcharts Jan. 14 at 11:23 AM
$BCTX and $SPRC WHENEVER THERE'S GREAT NEWS WATCH FOR THE RUG. BIO TECH RUGS
0 · Reply
roaringcharts
roaringcharts Jan. 14 at 10:48 AM
$SPRC Just look at the charts after a RS.
0 · Reply
69z28
69z28 Jan. 14 at 9:57 AM
$SPRC Ready for this to dip & buy it up!
0 · Reply
MovingFast77
MovingFast77 Jan. 14 at 2:52 AM
$SPRC
0 · Reply
Enzo4u
Enzo4u Jan. 14 at 12:36 AM
$SPRC Will we see another pump?
0 · Reply
roaringcharts
roaringcharts Jan. 13 at 11:00 PM
$SPRC so the ceo here is oz adler is a director at$PLRZ $CMND and they destroyed plrz reverse split after reverse split before it ran so don't be surprised if he hits another offering asap. Offering closes tomorrow so let's see
1 · Reply
Malandro2410
Malandro2410 Jan. 13 at 10:53 PM
$SPRC I hope everyone sells there shares on these bums! You put news out on the day of an offering to destroy the people holdings pockets. Im glad i seen this today and if I were you I would sell on them and drive the price to nothing with there ti y marketcap. That was cringe and disgusting wbt they did to yall. I hope you guys make your money back!
0 · Reply
BreakoutBullz
BreakoutBullz Jan. 13 at 10:23 PM
🛎️ Trade Recap 🛎️ $EVTV ran 🔥💰🎯 +633% from initial .67 call! $AHMA ran 🔥💰🎯 +146% from 6.60 call! $XAIR ran 🔥💰🎯 +105% from 1.30 call! $GELS ran 🔥💰🎯 +53% from 1.10 call! $SPRC ran 🔥💰🎯 +32% from 1.80 call!
0 · Reply
Enzo4u
Enzo4u Jan. 13 at 9:50 PM
$SPRC still a low float even after the offering, but def a turd
0 · Reply
Zackpedia
Zackpedia Jan. 13 at 9:39 PM
$SPRC Told you!
0 · Reply
roaringcharts
roaringcharts Jan. 13 at 9:25 PM
$SPRC atleast they're saving on kosher meals with only two employees
0 · Reply
Malandro2410
Malandro2410 Jan. 13 at 9:22 PM
$SPRC This thing is going to zero two employees. They got enough money for mcdonalds now 🤣😭
0 · Reply
Arsya
Arsya Jan. 13 at 9:16 PM
$SPRC do yourselves a favour and stay away from this stock
0 · Reply
Malandro2410
Malandro2410 Jan. 13 at 9:08 PM
$SPRC Just when you thought you out of the woods lets dump it once more for the crowd 🤣😭🤣😭
0 · Reply
roaringcharts
roaringcharts Jan. 13 at 9:03 PM
$SPRC looked at the balance sheets and wondered where the money came from to acquire anything here. They have no money.
1 · Reply
Malandro2410
Malandro2410 Jan. 13 at 9:02 PM
$ATON Offerings happening everywhere. All the companies are broke $SPRC as well today. Crazy!!
0 · Reply
ParabolicWhisper
ParabolicWhisper Jan. 13 at 8:58 PM
$FIGR $STX $SPRC $XPEV thoy
0 · Reply
mkstar1
mkstar1 Jan. 13 at 8:51 PM
$SPRC coiling hard, with acquisition should jump
0 · Reply
Malandro2410
Malandro2410 Jan. 13 at 8:50 PM
$ATON Wow $SPRC did the same thing today run up sixty percent and direct offering dollar land. This is crazy honestly!
0 · Reply
Malandro2410
Malandro2410 Jan. 13 at 8:46 PM
$ATON $SPRC just did this. Seems like a lot of them scamming away. Might be the trend of offerings after runs be super cautious. Its a circus and im the clown leading it. I love this shit!!
0 · Reply
Malandro2410
Malandro2410 Jan. 13 at 8:42 PM
$SPRC A nice sell off into close after a fifty oercent drop today. Good job Israel very trustworthy company with your 2 employees.
0 · Reply
BigG_Money
BigG_Money Jan. 13 at 8:23 PM
$SPRC Blast off AH's
0 · Reply